New York, December 2021: Axiom Market Research & Consulting™ added a report on pulmonary arterial hypertension market which includes study on drug class, type, diagnosis, treatment, end users, sales channel, and geography. Pulmonary Arterial Hypertension Market was projected to grow at a CAGR of 5.77% for the forecast period 2022 to 2028. The global market is estimated and forecasted in terms of revenue (USD Million) generated by the pulmonary arterial hypertension market.

The factors such as advancement of the new technology, along with increasing burden of the pulmonary arterial hypertension as the prevalence and incidence of the PH based on the population has proven to be challenging due to the lack of the specificity of the diagnosis, and the private and government support for the development of the orphan drugs have been driving the growth of the pulmonary arterial hypertension market during the forecast period. 

The report analyses the pulmonary arterial hypertension market based on drug class, type, diagnosis, treatment, end users, sales channel and geography. By drug class, the pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and PDE-5 dipsticks. By type, the pulmonary arterial hypertension market is segmented into idiopathic, heritable and associated. By diagnosis, the pulmonary arterial hypertension market is segmented into blood tests, chest X-Ray, electrocardiogram (ECG), echocardiogram, right heart catheterization, and polysomnogra. By treatment, the pulmonary arterial hypertension market is segmented into medication, surgery and therapy. By end users, the pulmonary arterial hypertension market is segmented into hospitals, specialty clinics and home healthcare. By sales channel, the pulmonary arterial hypertension market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Geographically, the pulmonary arterial hypertension market is studied for the regions including North America, Europe, Asia Pacific, and Rest of the World. 

Endothelin antagonists receptors (ERAs) drug class segment is estimated to have significant market share in the pulmonary arterial hypertension market

The factors such as advanced management of hypertension, as the endothelin has been one of the most potent vasoconstrictors and has significant increase in the sales of the drugs have been responsible for propelling the growth of the segment in the pulmonary arterial hypertension market during the forecast period. 

Idiopathic type segment is the major type of the disease observed in the pulmonary arterial hypertension market 

The disease is a high blood pressure in the arteries of the lungs, and the right side of the heart mainly works harder in this disease for the purpose of pushing the blood to the lungs, and the growth of the segment has been ultimately driving the demand of the pulmonary arterial hypertension market during the forecast period. 

Blood test diagnosis segment is mostly done to identify the disease in the pulmonary arterial hypertension market

The factors such as easy availability and detection of the pulmonary disease has been responsible for driving the growth of the segment in the pulmonary arterial hypertension market during the forecast period. 

Therapy treatment segment is widely used in the pulmonary arterial hypertension market

The therapy treatment type is widely used or preferred for the purpose preventing the disease from getting worse driving the growth of the segment in the pulmonary arterial hypertension market during the forecast period. 

Hospital end user segment is leading the pulmonary arterial hypertension market

Because of the advanced services like the diagnosis tools and the facilities provided for the treatment of the patients, along with increasing inflow of the patients in the hospitals has been propelling the growth of the segment in the pulmonary arterial hypertension market during the forecast period. 

Hospital pharmacy sales channel segment is leading the pulmonary hypertension market

The professionalization of the functioning of the pharmaceutical services in the hospitals along with the providing help for the medical staff, patients, nurses and other have been involved in the patient care on the use of the drugs, along with toxicity, possible side effects and drug interaction has been propelling the growth of the segment in the pulmonary arterial hypertension market during the forecast period. 

North America is expected to dominate the pulmonary hypertension market

The increase in the healthcare expenditure and core manufacturing, along with the growing awareness about the pulmonary arterial hypertension and increasing diagnosis for the disease has been propelling the growth of the pulmonary arterial hypertension market in the region during the forecast period. 

Key Players

The key players in the pulmonary arterial hypertension market are Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson (Actelion Pharmaceuticals, Ltd.), Merck & Co. Inc., Novartis International AG, Pfizer, Inc. and United Therapeutics Corporation among others.

Browse for More Details: https://www.axiommrc.com/product/10435-pulmonary-arterial-hypertension-market-report

Contact Us:

Ganesh Sai

United States

3 Germay Dr.Ste 4 - 4666

Wilmington DE 19804

U.S.:- + 1 (845) 875-9786

U.K.:- + 44 (0) 20 3286 9707

Email: sales@axiommrc.com